News Aldeyra’s reproxalap for dry eye disease accepted by FDA Biotech Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New D
News Aldeyra spies FDA filing ahead for dry eye drug reproxalap Aldeyra Therapeutics' dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off.
News Aldeyra builds case for troubled dry eye drug reproxalap Prospects for Aldeyra's dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn't giving up and h
News ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
